Transplant Biomedicals Announces Positive Interim Results For Study Of VIVIAN Device

“These results are in full alignment with our pre-clinical experience and fully support the idea that our disrupting platform that combines hypothermia and low frequency/energy ultrasounds can play a relevant role in addressing the current unmet medical needs not covered by the standard-of-care in solid organ preservation, static cold storage,” said Dr. Carmen Peralta, co-founder and chief science officer of Transplant Biomedicals

Sourced through from: